Published in Am J Cardiol on September 01, 1981
Athlete's heart or hypertrophic cardiomyopathy? Clin Res Cardiol (2008) 2.32
Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart (1997) 1.72
Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J (1990) 1.49
A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A (1993) 1.47
Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart (1999) 1.45
Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest (1990) 1.42
Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J Clin Invest (1992) 1.30
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart (2005) 1.24
Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart (2005) 1.15
Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy. Br Heart J (1992) 1.15
Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. Br Heart J (1990) 1.06
Sudden death from cardiovascular disease in young athletes: fact or fiction? Br J Sports Med (1997) 1.03
Ras-dependent pathways induce obstructive hypertrophy in echo-selected transgenic mice. Proc Natl Acad Sci U S A (1997) 1.01
Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes. Br Heart J (1993) 0.98
DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart (1996) 0.97
Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J Med Genet (1999) 0.95
Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes. J Am Heart Assoc (2014) 0.94
Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics. Neth Heart J (2007) 0.93
Clinical and prognostic evaluation of familial hypertrophic cardiomyopathy in two South African families with different cardiac beta myosin heavy chain gene mutations. Br Heart J (1995) 0.93
Myocardial diseases of animals. Am J Pathol (1986) 0.93
Clinical implications of hypertrophic cardiomyopathy associated with mutations in the alpha-tropomyosin gene. Heart (1996) 0.91
Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol (2005) 0.89
Left ventricular strain and untwist in hypertrophic cardiomyopathy: relation to exercise capacity. Am Heart J (2010) 0.87
Mechanism of systolic anterior motion of mitral valve and site of intraventricular pressure gradient in hypertrophic obstructive cardiomyopathy. Br Heart J (1983) 0.86
Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy. Heart (1996) 0.85
Multiple disease genes cause hypertrophic cardiomyopathy. Br Heart J (1994) 0.84
Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. Am J Cardiol (2013) 0.83
Familial spontaneous complete heart block in hypertrophic cardiomyopathy. Br Heart J (1986) 0.82
Clinical and imaging description of the Maron subtypes of hypertrophic cardiomyopathy. Int J Cardiovasc Imaging (2014) 0.82
Endogenous endothelin 1 mediates angiotensin II-induced hypertrophy in electrically paced cardiac myocytes through EGFR transactivation, reactive oxygen species and NHE-1. Pflugers Arch (2013) 0.80
Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. Br Heart J (1984) 0.80
Hypertrophic cardiomyopathy in the elderly. Br Heart J (1990) 0.80
Cardiomyopathies in children. Korean J Pediatr (2013) 0.80
Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration. Heart (1997) 0.79
Effects of hypertrophy and fibrosis on regional and global functional heterogeneity in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging (2012) 0.77
Prognostic value of iodine-123 metaiodobenzylguanidine imaging in patients with heart failure. Exp Clin Cardiol (2003) 0.77
Hypertrophic Cardiomyopathy: Prevalence, Hypertrophy Patterns, and Their Clinical and ECG Findings in a Hospital at Qatar. Heart Views (2011) 0.76
MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors. Int J Cardiovasc Imaging (2012) 0.76
Survival and clinical behavior of hypertrophic cardiomyopathy in a latin american cohort in contrast to cohorts from the developed world. J Cardiovasc Ultrasound (2015) 0.75
The role of echocardiography in the assessment of hypertrophic cardiomyopathy. Postgrad Med J (1986) 0.75
Familial hypertrophic cardiomyopathy: vectorcardiographic findings in echocardiographically unaffected relative. Br Heart J (1982) 0.75
Hypertrophic Cardiomyopathy in a Young Adult with RV Aneurysm: Report of a Rare Finding and Review of the Literature. Heart Views (2011) 0.75
Progression of hypertrophic cardiomyopathy. A cross sectional echocardiographic study. Br Heart J (1985) 0.75
Haemodynamic effects of short term intravenous amiodarone for hypertrophic cardiomyopathy. Br Heart J (1988) 0.75
Short- and long-term effects of nisoldipine on cardiac function and exercise tolerance in patients with hypertrophic cardiomyopathy. Basic Res Cardiol (1997) 0.75
Detraining-related changes in left ventricular wall thickness and longitudinal strain in a young athlete likely to have hypertrophic cardiomyopathy. J Sports Sci Med (2012) 0.75
Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy. Cardiovasc Ultrasound (2016) 0.75
The systolic paradox in hypertrophic cardiomyopathy. Open Heart (2017) 0.75
Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol (1997) 7.45
Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol (2000) 7.39
Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res (2004) 6.49
Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation (2004) 6.43
Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science (1998) 5.98
Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med (1990) 5.91
Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci (2001) 5.09
Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science (1994) 4.94
An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis) N Engl J Med (1998) 4.92
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med (1998) 4.29
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med (2000) 3.99
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med (1991) 3.80
Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med (1996) 3.40
Profile of preparticipation cardiovascular screening for high school athletes. JAMA (1998) 3.36
Asymmetric septal hypertrophy. Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation (1973) 3.31
Colitis cystica profunda. Am J Clin Pathol (1966) 3.28
The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med (1991) 3.17
Sudden death in young athletes. Circulation (1980) 3.05
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary-artery disease. N Engl J Med (1977) 2.94
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol (2001) 2.93
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med (1987) 2.88
Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation (1979) 2.68
Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol (1995) 2.62
Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol (2000) 2.61
Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation (1989) 2.56
"Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol (1988) 2.53
Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol (2001) 2.49
A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med (1989) 2.45
Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol (2000) 2.33
Causes of sudden death in competitive athletes. J Am Coll Cardiol (1986) 2.31
Comparative left ventricular dimensions in trained athletes. Ann Intern Med (1975) 2.27
Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol (2001) 2.22
Prognosis of surgically corrected coarctation of the aorta. A 20-year postoperative appraisal. Circulation (1973) 2.21
Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol (1986) 2.18
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med (1987) 2.18
Preparticipation cardiovascular screening for US collegiate student-athletes. JAMA (2000) 2.10
Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens (1995) 2.09
Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation (1976) 2.08
Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol (2000) 2.05
Physiologic left ventricular cavity dilatation in elite athletes. Ann Intern Med (1999) 2.05
Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation (2000) 2.03
Impaired left ventricular diastolic filling in patients with coronary artery disease: assessment with radionuclide angiography. Circulation (1981) 2.00
Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med (1986) 2.00
Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation (2001) 2.00
Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation (1994) 1.98
Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis. N Engl J Med (1973) 1.96
Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation (1975) 1.96
Changes in heart rate and heart rate variability before ambulatory ischemic events(1). J Am Coll Cardiol (2001) 1.92
Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol (1981) 1.89
Importance of the design of an exercise protocol in the evaluation of patients with angina pectoris. Circulation (1971) 1.89
Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1993) 1.89
Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation (1982) 1.87
Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH). Light and electron microscopic findings. Circulation (1974) 1.85
Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care (2001) 1.84
Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med (1966) 1.83
Angina caused by reduced vasodilator reserve of the small coronary arteries. J Am Coll Cardiol (1983) 1.82
Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation (1985) 1.81
Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation (1979) 1.80
Sudden death in patients with hypertrophic cardiomyopathy: characterization of 26 patients with functional limitation. Am J Cardiol (1978) 1.78
"Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol (1978) 1.76
Structural features of the athlete heart as defined by echocardiography. J Am Coll Cardiol (1986) 1.70
Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol (1984) 1.67
Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation (1981) 1.66
The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis (2000) 1.66
Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.65
Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation (1982) 1.64
Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol (1979) 1.63
Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation (1992) 1.63
Relief of angina pectoris by electrical stimulation of the carotid-sinus nerves. N Engl J Med (1967) 1.61
Limitations of the electrocardiographic response to exercise in predicting coronary-artery disease. N Engl J Med (1975) 1.61
Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation (2001) 1.61
Myotonic heart disease: a clinical follow-up. Neurology (1991) 1.60
Noninvasive assessment of left ventricular diastolic function: comparative analysis of Doppler echocardiographic and radionuclide angiographic techniques. J Am Coll Cardiol (1986) 1.59
Ultrastructural features of degenerated cardiac muscle cells in patients with cardiac hypertrophy. Am J Pathol (1975) 1.59
A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res (1998) 1.59
Left ventricular mass in the elderly. The Cardiovascular Health Study. Hypertension (1997) 1.59
Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol (1987) 1.57
Asymetric septal hypertrophy in childhood. Circulation (1976) 1.56
Myocardial adenyl cyclase: activation by thyroid hormones and evidence for two adenyl cyclase systems. J Clin Invest (1969) 1.56